Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants

NCT06741657 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT06741657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06741657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
January 2, 2025
Completion date
March 10, 2026
Enrollment
404 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer